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Objective: Subclinical hypothyroidism (SH) is quite common in children and adolescents. The natural
history of this condition and the potential effects of replacement therapy need to be known to properly
manage SH. The aim of this review is to analyze: i) the spontaneous evolution of SH, in terms of
the rate of reversion to euthyroidism, the persistence of SH, or the progression to over hypothyroidism;
and ii) the effects of replacement therapy, with respect to auxological data, thyroid volume, and
neuropsychological functions.
Methods: We systematically searched PubMed, Cochrane, and EMBASE (1990–2012) and identified 39
potentially relevant articles of which only 15 articles were suitable to be included.
Results and conclusions: SH in children is a remitting process with a low risk of evolution toward overt
hypothyroidism. Most of the subjects reverted to euthyroidism or remained SH, with a rate of evolution
toward overt hypothyroidism ranging between 0 and 28.8%, being 50% in only one study (nine
articles). The initial presence of goiter and elevated thyroglobulin antibodies, the presence of celiac
disease, and a progressive increase in thyroperoxidase antibodies and TSH value predict a progression
toward overt hypothyroidism. Replacement therapy is not justified in children with SH but with TSH
5–10 mIU/l, no goiter, and negative antithyroid antibodies. An increased growth velocity was observed
in children treated with levothyroxine (L-T4; two articles). L-T4 reduced thyroid volume in 25–100%
of children with SH and autoimmune thyroiditis (two studies). No effects on neuropsychological
functions (one study) and posttreatment evolution of SH (one study) were reported.
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Subclinical hypothyroidism (SH) is biochemically
defined as a serum TSH concentration above the
statistically defined upper limit of the reference range
when serum-free thyroxine (fT4) concentration is
within its reference range (1, 2). The clinical presen-
tation varies widely, ranging from no manifestations
to clear signs or symptoms of hypothyroidism.
SH prevalence in the adult population is reported to
be 1–10%, being higher in the elderly population, in
females, and in white subjects (3, 4, 5). In the pediatric
population, SH prevalence is reported to be slightly
lower than 2%, even if epidemiological studies concern-
ing childhood and adolescence are scanty. Therefore,
SH is quite a common disorder in pediatric patients,
and both primary care physicians and pediatric
endocrinologists frequently face the decision of what
to do regarding these children.
In order to adequately manage a case of SH, it is of
paramount importance to know how this condition willndocrinologyevolve and when it should be treated. The natural
course of SH in adults seems to progress to overt
hypothyroidism (reduced circulating thyroid hormones)
in proportions ranging from !1 up to 20% according
to different studies (1, 3, 4), with higher rates of
progression in patients with higher baseline serum
TSH concentration, elevated antithyroid autoanti-
bodies, and a higher degree of hypoechogenicity at
thyroid ultrasound (6, 7). In addition to the risk of
progression to overt hypothyroidism, in the decision to
treat or not a condition of SH, the clinician should also
consider the systemic consequences of leaving the
hyperthyrotropinemia untreated. In adults, SH has
been associated with an increased risk for coronary
and other heart diseases, peripheral arterial diseases
(8, 9, 10, 11), depression (12), and various bio-
chemical abnormalities, including elevated LDL
cholesterol, increased serum prolactin concentrations,
and a negative influence on the hemostatic profile
(8, 13, 14, 15, 16). On the other hand, the risks
of an overtreatment should be likewise considered.DOI: 10.1530/EJE-12-0656
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thyroidism, which has been reported to be responsible
for significant bone loss in postmenopausal women
(17, 18) and atrial fibrillation in older patients (19).
Moreover, potential benefits of higher TSH levels such
as longevity and a lower all-cause mortality have been
suggested by recent studies (20, 21).
Studies regarding the natural history of SH and its
consequences in childhood are lacking and very few
studies have examined the effects of levothyroxine (L-T4)
replacement therapy in young people with SH. The aim
of this review is to summarize what is known about
the natural course of SH in children and adolescents
and the potential effects of a replacement therapy.Materials and methods
Literature search
We systematically searched PubMed, Cochrane, and
EMBASE (January 1990–July 2012) to identify studies
evaluating the natural history of SH and the efficacy of
replacement therapy with L-T4 in children and
adolescents.
The search terms used included ‘SH’, ‘hyperthyro-
tropinemia’, ‘child$’ (or ‘adolescent$’), and ‘history’ or
‘course’ or ‘evolution’ and ‘treatment’ or ‘therapy’.
These terms were combined in various ways to generate
a wide search. In addition, we checked the references of
eligible articles for further papers that were not
captured by our search strategy and corresponded
with authors when a full-length article was not
available directly online or when relevant information
was missing in the paper.Inclusion and exclusion criteria
For the analysis of the natural history of SH, we
included only full-length articles that met the following
predetermined criteria: i) longitudinal or retrospective
studies regarding the natural history of SH in the
pediatric age; ii) studies evaluating the spontaneous
evolution of SH, in terms of rate of reversion to
euthyroidism, persistence of SH, or progression to over
hypothyroidism; iii) no studies on pharmacological or
lifestyle intervention that might interfere with SH
natural evolution; iv) no studies including patients
with chronic systemic diseases, genetic syndromes, or
taking concomitant therapy with either lithium salts,
antiepileptic agents, glucocorticoids, or iodinated drugs;
and v) studies in the English language.
For the analysis of the potential effects of replacement
therapy on SH, we included only full-length articles that
met the following predetermined criteria: i) clinical
trials performed in pediatric patients reporting on the
efficacy of replacement therapy with L-T4 in SH; ii) no
studies including patients with chronic systemicwww.eje-online.orgdiseases, genetic syndromes, or taking concomitant
therapy with either lithium salts, antiepileptic agents,
glucocorticoids, or iodinated drugs; and iii) studies in
the English language.Data extraction and synthesis
A form was generated to register whether individual
studies met eligibility criteria and to collect data
regarding the study design and methodological quality.
Three investigators independently reviewed and
extracted data from the papers according to the
predetermined criteria. Any difference in opinion
about the studies was resolved by discussion between
the investigators.
Outcome measures
In the analysis of the studies concerning the natural
history of SH, we focused on the following measures:
i) rate of reversion to euthyroidism (normal TSH and
thyroid hormone levels); ii) rate of persistence of SH
(normal thyroid hormone levels with stably elevated or
even raised TSH levels); and iii) rate of progression to
overt hypothyroidism (high TSH levels with reduced
thyroid hormone levels). Owing to the low number of
studies analyzing the effects of replacement therapy for
SH and the lack of common outcomes, the therapeutic
efficacy of L-T4 was evaluated by reporting the specific
results of each study.Analysis
Selection bias and lack of common outcome measures
were some of the problems that prevented a proper meta-
analysis. Although this review is not a meta-analysis, we
critically assessed the literature and tried to identify
high-quality studies. In the evaluation of replacement
therapy, wherever possible, preference was given to
randomized controlled trials and longitudinal studies.
Very few reports, however, had such characteristics;
therefore, we included other types of clinical trials.
Moreover, we examined whether the control group was
appropriate and whether overtreatment was avoided.
Lastly, we evaluated whether correct statistical analyses
were applied in the selected studies.Results
Natural history of SH in children and
adolescents
The literature search we performed identified 27
potentially relevant articles. After reviewing titles,
abstracts, and the full-length texts, nine articles were
selected for closer assessment and then included in our
analysis (22, 23, 24, 25, 26, 27, 28, 29, 30). They are
summarized in Table 1.
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R4 A Monzani and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2013) 168Of the nine selected studies, six were longitudinal
trials (22, 23, 25, 26, 27, 29) and three were
retrospective (24, 28, 30). Five were single center
studies (22, 23, 26, 27, 29) and four were multicenter
studies (24, 25, 28, 30). Overall, data from a total of
4018 children were reported, with most studies
including a small number of subjects and only one
retrospective study including a very large study
population (28). In most studies, the patient population
was represented by subjects with autoimmune
thyroiditis, the most frequent cause of SH in pediatric
age (22, 23, 24, 26, 27, 30), in one study by subjects
with elevated TSH levels at newborn screening (29), in
another by subjects with SH of unidentified origin
(idiopathic SH) (25), in one by subjects with isolated
hyperthyrotropinemia (30), and in another by children
in a health care system who had undergone TSH
determination, without any known thyroid illness (28).
Children’s age showed a wide range of variability,
ranging from 6 months to 19 years. The follow-up
duration after the diagnosis of SH varied from a period
of 2 to 9.5 years.
In the study by Gopalakrishnan et al. (22), out of
32 Indian children and adolescents with goitrous
autoimmune thyroiditis followed for a minimum
period of 2 years, seven (21.9%) had their TSH
normalized, 21 (65.6%) remained in a condition of SH,
and only four (12.5%) developed overt hypothyroidism.
Zois et al. (23) reported the persistence of SH in all
seven Greek adolescents with autoimmune thyroiditis
followed for 5 years. They also showed that thyroid
hypoechogenicity and anti-thyroperoxidase (TPO-Ab)
and anti-thyroglobulin antibodies (TG-Ab) increased
over time.
In the retrospective multicenter study by Radetti et al.
(24), out of 55 Italian children with Hashimoto’s
thyroiditis, during the follow-up, 16 (29.1%) became
euthyroid and the remaining 39 children remained SH.
Of those that remained SH, 16 (29.1%) had a TSH value
that was one- to twofold above the upper normal limit,
while 23 (41.8%) had a TSH value that increased more
than twofold above the upper normal limit. As L-T4
treatment was started and patients were excluded from
the study as their TSH became twofold above the upper
normal limit, it was not possible to state how many
children would have actually developed an overt
hypothyroidism. The authors also reported that the
presence of goiter and elevated TG-Abs at presentation
and a progressive increase in TPO-Abs and TSH value
may be predictive of the development of hypothyroidism
for the group as a whole, even if none of these
parameters could predict the deterioration of thyroid
function in individual subjects. When analyzing the
presence of signs of impaired thyroid function, the
statural growth was normal during the entire obser-
vation period in all patients and no significant difference
in BMI SDS was found between the patients,www.eje-online.orgindependent of the evolution of their thyroid function
during the study period.
Wasniewska et al. (25), who followed for 2 years, 92
Italian children with ‘idiopathic’ SH, defined an
incidental finding of elevated TSH for which all
etiological causes of SH had been excluded. They
reported that 38 (41.3%) patients normalized their
TSH, 54 (58.7%) remained SH, 43 (46.7%) with a TSH
5–10 mIU/l, and 11 (12%) with an increased TSH
O10 mIU/l (10.5–15 mIU/l); however, amongst these,
none developed an overt hypothyroidism. Neither TSH
and fT4 values at entry nor the presence of a family
history of thyroid diseases were predictive of the
normalization of TSH or persistence of SH. None of the
children showed any symptoms of hypothyroidism
during follow-up and no changes in height and BMI
were observed throughout the observation period.
Moore (26) studied 18 American patients with
autoimmune thyroiditis and elevated TSH concen-
tration, of which 11 were never treated and seven
were followed for at least 1 year after the discontinu-
ation of treatment. During the observation period, TSH
normalized in seven subjects, TSH remained increased
with normal fT4 levels in ten, and only one patient
developed an overt hypothyroidism.
In the study by Jaruratanasirikul et al. (27), out of
eight Thai girls with SH in Hashimoto’s thyroiditis, after
6 years of follow-up, four (50%) recovered normal
thyroid function without any medication and the other
four patients developed an overt hypothyroidism, which
was treated by T4. The authors reported that goiter size
remained unchanged without medication, that no
clinical or biochemical markers at baseline were able
to predict who will become euthyroid or hypothyroid,
and that all eight SH patients achieved their final height
and entered puberty at a normal age, regardless of the
evolution of their thyroid function.
Lazar et al. (28) in their retrospective multicenter
study analyzed a database of 121 052 children aged
0.5–16 years who had a TSH measured in 2002 and
were followed to 2007. They reported that about 3%
(3632 subjects) had SH according to the first TSH
evaluation. During the 5-year follow-up, TSH values
tended to normalize proportionally to the degree of the
TSH elevation at the initiation of the study. In subjects
with TSH O5.5–%10 mIU/l, 73.6% normalized their
TSH, about 25% maintained that range, about 2% had
their TSH increased O10 mIU/l but with normal fT4,
and 0.03% developed an overt hypothyroidism that
required medical treatment. In subjects with TSH
O10 mIU/l, 40% normalized their TSH, 33.1% reduced
their TSH to a value between 5.5 and 10 mIU/l, 24.9%
maintained their TSHO10 mIU/l, and 0.2% developed
an overt hypothyroidism that was treated. Predictive
factors for a sustained highly elevated TSH (O10 mIU/l)
were an initial TSH O7.5 mIU/l and female gender,
whereas age was not found to be a predictive factor.
Subclinical hypothyroidism in children R5EUROPEAN JOURNAL OF ENDOCRINOLOGY (2013) 168Leonardi et al. (29) studied a group of Italian children
‘false positive’ to neonatal screening for congenital
hypothyroidism, who had normal fT4 and normal or
slightly elevated TSH values at the recall examination at
a mean of 22 days of life. When retested at 2–3 years of
age, 28 of them had SH (TSH 4–10.1 mIU/l with
normal fT4). Twenty of these 28 children were treated
with a replacement therapy and then withdrawn from
therapy 2–3 months before reevaluation. Out of the
28 children with SH, at 4.1–6.6 years of age, TSH
was normal in nine children (32%) and persistently
elevated in the remaining 19 (68%), ranging between 4
and 9.2 mIU/l. At 7.2–9.5 years of age, TSH remained
normal in the nine children who previously normalized
their thyroid function, returned to normal in five out of
19 of the children with a previous elevated TSH value,
and persisted above normal in the remaining 14,
ranging between 4.1 and 8.2 mIU/l. On the whole,
half of the children (14 out of 28) reverted to
euthyroidism at the end of the observation period,
while the rest remained SH, with none of the children
developing an overt hypothyroidism. Studying thyroid
morphology, the authors showed the presence of
hemiagenesis, hypoplasia of one lobe, or goiter in half
of these children and detected gene mutations in two
children (TPO and TSH-R mutation respectively).
Therefore, the authors concluded that a mild hyper-
thyrotropinemia at neonatal screening, in particular
when these data are confirmed at a further evaluation,
may be suggestive of congenital anatomic or functional
anomalies of the thyroid gland. These data remain
to be confirmed in further evaluations and the
clinical significance resolved, as none of the studied
children developed an overt hypothyroidism during the
follow-up.
Finally, in the recent retrospective study by Radetti
et al. (30), the natural evolution of 87 SH children with
autoimmune thyroiditis and 59 children with isolated
hyperthyrotropinemia was analyzed after a 3-year
period. Out of 87 children with autoimmune thyroiditis,
17 (19.5%) remained stable in their SH condition,
36 (41.4%) normalized their TSH, and 34 (39.1%)
developed an overt hypothyroidism. Out of 59 children
with isolated hyperthyrotropinemia, 28 (47.5%)
remained stable in their SH condition, 23 (39%)
normalized their TSH, and only eight (13.5%) developed
an overt hypothyroidism. The authors also investigated
possible predictive factors for the development of
hypothyroidism and found that in patients with
autoimmune thyroiditis, the presence of celiac disease,
elevated TSH, and TPO-Abs increased the risk of
developing hypothyroidism by 4-, 3.4-, and 3.5-fold
respectively whereas no predictive factor was identified
in patients with isolated hyperthyrotropinemia.
In particular, they found that in patients with
autoimmune thyroiditis, the increase in TSH levels
was strongly predictive of the development of
hypothyroidism.Effects of replacement therapy for SH in
children and adolescents
Our literature search identified 12 potentially relevant
articles. After reviewing the titles, abstracts, and the
full-length articles, six were selected for a closer
assessment and included in this review (31, 32, 33,
34, 35, 36). They are summarized in Table 2.
Of the six selected studies, three were retrospective
trials (32, 34, 35), one of which was a case–control
study (32), and three were longitudinal trials (31, 33,
36), of which one was a crossover study (where L-T4 was
compared with no treatment) (36). Five studies were
single center studies (31, 32, 34, 35, 36) and one a
multicenter (33). Overall, data from a total of 202
children were reported. In two studies, the patient
population was represented by subjects with an
autoimmune thyroiditis (34, 35), in one study by
subjects with both congenital and acquired SH of
unspecified origin (36), in one study by children with
mild and idiopathic SH (33), in one other by children
with type 1 diabetes (32), and in another one by children
with short stature (31). Children’s age varied between
2.1 and 18.5 years. The treatment duration varied
widely, ranging from 6 weeks to 12 years. The L-T4
dosage varied between 2 and 4 mg/kg per day, was not
available in two studies (34, 36), and in one study the
dosage per kilogram body weight was not reported (35).
The longitudinal study by Cetinkaya et al. (31)
included 24 prepubertal and 15 pubertal Turkish
children complaining of short stature, in which SH
was diagnosed by TRH stimulation test. They received
L-T4 at 2 mg/kg per day for 1 year. After both 6 months
and 1 year of treatment, growth velocity and growth
velocity SDS were significantly increased in prepubertal
and pubertal subjects, even if the improvement
was more significant in the pubertal group. The
authors reported no signs of clinical hyperthyroidism
in any patient.
In the retrospective study by Chase et al. (32),
25 American children with SH and type 1 diabetes
were matched to 25 diabetic controls. Five of the 25
cases were pubertal and 20 prepubertal. The 25 diabetic
children with SH received L-T4 at 2–4 mg/kg per day
for 2 years, with TSH and T4 determinations at least
twice yearly to adjust the dosage in order to keep their
levels within the normal range. The authors showed
a significant improvement in growth velocity after L-T4
treatment in prepubertal children compared with
diabetic controls, with this improvement more signi-
ficant in children with higher TSH values at entry.
No significant difference was found in growth velocity
between pubertal children and diabetic controls and
in height Z-scores between all treated children and
diabetic controls.
In the longitudinal study by Wasniewska et al. (33),
69 Italian patients with mild (TSH 5–10 mIU/l) and
idiopathic SH were treated with L-T4 for 2 years andwww.eje-online.org
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Subclinical hypothyroidism in children R7EUROPEAN JOURNAL OF ENDOCRINOLOGY (2013) 168evaluated 3 months after therapy withdrawal. The
starting dose was 2 mg/kg per day. The 69 treated
children were compared with a cohort of 92 untreated
children matched for age and thyroid function
followed for 2 years. At the end of follow-up, the
prevalence of those who normalized, maintained, or
increased O10 mIU/l their TSH value was similar
between the treated and untreated children. In treated
children, TSH values at baseline were predictive of
TSH values 3 months after treatment withdrawal. No
effects of therapy on height and BMI SDS were found;
however, growth velocity was not reported.
Svensson et al. (34) in their retrospective study
analyzed data in 42 Swedish children with SH and
autoimmune thyroiditis who were treated with L-T4. A
significant reduction in median thyroid volume SDS was
seen at each 2-year assessment during the therapy.
Correlations were found between the reduction in
thyroid volume SDS and the thyroid volume SDS at
baseline, the treatment duration, and TSH and T4 levels
at baseline. No complications with the L-T4 treatment
were reported during the study period.
The retrospective study by Rother et al. (35) reported
the effects of L-T4 in 16 American children with
autoimmune thyroiditis treated for a period ranging
from 1 to 12 years. In 75% of them, no changes in
thyroid volume were observed, whereas in the remain-
ing 25% a reduction in goiter size took place.
In the study by Ajiaz et al. (36), the possible effects of
T4 therapy on cognitive functions of children with SH
were investigated. Indeed, no effects on neuropsycholo-
gical functions were shown in the 6- to 8-week
observation period; in particular, no improvement in
problems of attention was reported.Discussion
The first aim of our review was to critically assess the
studies evaluating the natural course of SH in child-
hood. The main limits of this analysis were the low
number of patients included in most of the studies and
the high heterogeneity of the study populations. Despite
such limits, the studies analyzed as a whole seem to
show that SH in children and adolescents is a benign
and remitting process with a low risk of evolution
toward an overt hypothyroidism. Indeed, most of the
subjects included in the studies reverted to euthyroidism
or remained SH, sometimes with an increase in TSH
values. The rate of development of an overt hypothyr-
oidism ranged between 0% in three studies (23, 24, 25)
and 28.8%, with only one study (27) reporting an
evolution toward an overt hypothyroidism in a half of
the eight investigated children.
Notably, when signs of impaired thyroid function
were investigated, height, BMI, and the age of puberty
were found to be normal and no clinical manifestations
of hypothyroidism were reported, regardless of theevolution of thyroid function. In accordance with
these data, a recent Italian study analyzing growth
and intellectual parameters in a cohort of 36 children
with persistent idiopathic SH followed longitudinally for
a period of 2.0–9.3 years demonstrated no alterations in
growth, bone maturation, BMI status, and cognitive
functions in presence of persistently elevated TSH values
(37). Therefore, thyroid hormones involved in growth
and neurocognitive development seem to work properly,
regardless of the persistently elevated TSH, in the
absence of replacement therapy.
When analyzing which factors may possibly be
predictive of the natural course of SH, Radetti et al.
(24, 30) reported that the initial presence of goiter and
elevated TG-Abs, the presence of celiac disease, and a
progressive increase in TPO-Abs and TSH value may be
predictive of progression toward an overt hypothyroid-
ism. Lazar et al. (28) reported that an initial TSH higher
than 7.5 mIU/l and the female gender are predictive
factors for a sustained highly elevated TSH.
The results regarding the natural history of SH in
children differ in some aspects from those reported in
elderly patients with SH (16). Studies in adults and the
elderly with idiopathic SH or SH in autoimmune
thyroiditis reported that the progression toward overt
hypothyroidism is quite common, with a low rate of
spontaneous normalization of TSH values (4, 6, 38). On
the other hand, similar to the elderly, the presence of
goiter, higher initial TSH levels, and positive antithyroid
antibodies were reported to be predictive factors of
evolution toward thyroid failure in children, even if
these data are not unanimously endorsed (24).
A special mention should be given to the results by
Leonardi et al. (29) who reported a high persistence of
SH in children ‘false positive’ at neonatal screening for
congenital hypothyroidism. In fact, even if none of the
children developed an overt hypothyroidism, pedia-
tricians should take into account that a newborn with
transient hyperthyrotropinemia at birth could be at risk
of developing SH later on in childhood.
Finally, many studies were excluded from our
analyses because rates of persistence of SH, reversion
to euthyroidism, or progression to overt hypothyroidism
according to our outcome measures were not available
(39, 40, 41, 42, 43, 44, 45, 46). All these studies were
focused on essential overweight or obesity, a clinical
condition frequently associated with SH (47). However,
none of them analyzed the natural course of SH without
any intervention. Indeed, a TSH normalization is
generally reported after weight loss but the mechanisms
underlying such thyroid hormonal changes in obese
children are far from clear. Furthermore, in the pediatric
setting, there are no controlled studies looking at the
outcomes of obese children with elevated TSH levels
treated with T4 vs placebo, with data regarding the
beneficial effects of replacement therapy still lacking.
As most studies in the pediatric age have shown that SH
is often a remitting or self-limiting process, the point ofwww.eje-online.org
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matter of debate. In the studies included in the second part
of this review, the efficacy of L-T4 treatment is shown in
respect to three main outcomes, i.e. auxological par-
ameters, goiter size, and neuropsychological functions.
Three studies analyzed the effect of L-T4 on growth
(31, 32, 33). Two of them (31, 32) found an increased
growth velocity in treated children, even if Chase et al.
(32) showed this result exclusively in prepubertal
children. However, it has to be underlined that in the
study populations, SH was not an isolated condition. On
the other hand, Wasniewska et al. (33) did not evaluate
growth velocity but reported no differences in height
and BMI between treated and untreated children.
Similar results were found in the abstract by Zen et al.
(48), who reported no differences in the growth velocity
SDS and height SDS in 20 treated and 26 untreated
children with short stature and SH.
Two studies focused on the effect on L-T4 on thyroid
volume (34, 35) and showed contrasting results. In the
study by Svensson et al. (34), a significant reduction in
thyroid volume of children with SH and autoimmune
thyroiditis was seen. On the contrary, Rother et al. (35)
reported a significant reduction in goiter size only in
25% of their children with SH and autoimmune
thyroiditis. One possible explanation for this different
outcome may be the different age at diagnosis of the
subjects included in the two studies. In particular, in the
study by Rother et al. (49), the children were peri-
pubertal and it is well known that a rapid increase in
thyroid volume normally takes place during puberty.
Moreover, it should be noted that the estimation of
thyroid volume was made by palpation in one study
(35) and by ultrasonography in the other (34).
Finally, only one study investigated the effect of L-T4 on
neurocognitive function (36). Even if T4 therapy is
known to have a significant long-term impact on
behavioral, locomotor, speech, hearing, and cognitive
abilities in children with congenital hypothyroidism as
the developing brain is more sensitive to thyroid hormone
deprivation (50), no effects of L-T4 on neuropsychological
functions of children with SH were reported in this study.
It has to be mentioned that children with SH had
attention problems when compared with healthy
controls and that these problems were subclinical in
the sense that they were not previously reported by
parents but were only detected by neuropsychological
tests. One possible explanation for the lack of effects
reported is the small sample size analyzed and the short
intervention period. On the whole, no clinical signs of
hyperthyroidism due to an overtreatment of SH were
reported in any of the reviewed studies. To our knowl-
edge, there are no studies in children up until now, which
have investigated the potential effects of replacement
therapy for SH or untreated hyperthyrotropinemia on
cardiovascular function, lipid profile, or bone mass, that
have been reported to be affected by TSH levels in adults
(8, 9, 10, 11, 13, 17, 18).www.eje-online.orgIndeed, the decision regarding the treatment of SH
continues to be controversial. The debate over treat-
ment of SH in adulthood has persisted for years and
review articles have been published both for (51, 52)
and against treatment (53, 54). In 2004 and 2005,
two expert panels came to different conclusions about
the management of SH in adults (1, 55). One expert
panel (1) concluded that patients with normal fT4 and
TSH O10 mIU/l may be treated, whereas it advised
follow-up of subjects with TSH in the range of
4.5–10.0 mIU/l because of insufficient evidence to
support treatment in these latter patients and because
of the concern of overtreatment. On the other hand, a
consensus statement jointly published by the American
Association of Clinical Endocrinologists, the American
Thyroid Association, and The Endocrine Society (55)
concluded that treatment of SH patients with TSH levels
of 4.5–10 mIU/l was appropriate, as the lack evidence of
benefit does not necessarily mean a lack of benefit.
Although both panels did not address the issue of SH in
the pediatric population, taking into account the low
rate of progression to an overt hypothyroidism,
treatment of SH in children should be indicated in the
presence of clinical signs or symptoms of impaired
thyroid function or goiter or TSH O10 mIU/l. L-T4
therapy may be beneficial when SH is associated with
short stature and impaired growth velocity or increased
thyroid volume. According to the available evidence,
hyperthyroidism due to an overtreatment of SH should
be considered an infrequent condition in the pediatric
age group. In children with SH but with no goiter,
negative antithyroid antibodies and TSH 5–10 mIU/l
replacement therapy are not justified, both because of
the low risk to develop an overt hypothyroidism and
that they could simply be euthyroid outliers, represent-
ing 2.5% of normal individuals whose TSH values are
above 97.5th percentile of euthyroid distribution. It has
to be taken into account that euthyroid outliers could be
carriers of polymorphisms or mutations in genes of the
thyroid hormone pathway such as TSH receptor, dual
oxidase 2 (DUOX2), phosphodiesterase 8B, and TPO
(56, 57, 58, 59, 60).Concluding remarks
i) SH in children seems to be a remitting process
with a low risk of evolution toward overt
hypothyroidism.
ii) The initial presence of goiter and elevated TG-Abs
and a progressive increase in TPO-Abs and TSH
values predict a progression toward overt
hypothyroidism.
iii) There is no clear evidence on the beneficial effects
of L-T4 on growth and thyroid volume in SH due to
insufficient data.
iv) No effects on neuropsychological functions were
reported.
Subclinical hypothyroidism in children R9EUROPEAN JOURNAL OF ENDOCRINOLOGY (2013) 168v) Replacement therapy is not justified in children
with SH but with TSH 5–10 mIU/l, no goiter, and
negative antithyroid antibodies.
vi) Further randomized double-blind studies are
needed to clearly evaluate the effects of replace-
ment therapy on growth, goiter, neuropsycholo-
gical, and cardiovascular outcomes.Declaration of interest
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